中国组织工程研究

中国组织工程研究 ›› 2011, Vol. 15 ›› Issue (12): 2129-2132.doi: 10.3969/j.issn.1673-8225.2011.12.010

• 复合支架材料 composite scaffold materials • 上一篇    下一篇

新型人源细胞混合型生物人工肝的安全性

简国登，张  志，汪  艳，周焕城，赵逸超，潘明新，高  毅   

  1. 南方医科大学珠江医院肝胆二科，广东省广州市 510280
  • 收稿日期:2010-12-14 修回日期:2011-01-29 出版日期:2011-03-19 发布日期:2011-03-19
  • 通讯作者: 潘明新，博士，主任医师，博士生导师，南方医科大学珠江医院肝胆二科，广东省广州市 510280 并列通讯作者：高毅，主任医师，教授，南方医科大学珠江医院肝胆二科，广东省广州市 510280
  • 作者简介:简国登★，男，1982年生，广东省佛山市人，汉族，南方医科大学在读硕士，医师，主要从事生物人工肝方面的研究。 Jianguodeng2009@163.com
  • 基金资助:

    国家高技术发展计划(863计划)，No. 2006AA02A141，人源细胞混合型生物人工肝的研制与开发。

Security of a new human hepatocyte hybrid bioartificial liver

Jian Guo-deng, Zhang Zhi, Wang Yan, Zhou Huan-cheng, Zhao Yi-chao, Pan Ming-xin , Gao Yi   

  1. Second Department of Hepatobiliary Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou  510280, Guangdong Province, China
  • Received:2010-12-14 Revised:2011-01-29 Online:2011-03-19 Published:2011-03-19
  • Contact: Pan Ming-xin, Doctor, Chief physician, Doctoral supervisor, Second Department of Hepatobiliary Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, Guangdong Province, China Gao Yi, Chief physician, Professor, Second Department of Hepatobiliary Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, Guangdong Province, China
  • About author:Jian Guo-deng★, Studying for master’s degree, Physician, Second Department of Hepatobiliary Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou 510280, Guangdong Province, China Jianguodeng2009@163.com
  • Supported by:

    National High Technology Research and Development Program of China (863 Program), No. 2006AA02A141*

PDF

454

被引次数

15

摘要：

背景：目前原位肝移植是惟一有效治疗急性肝衰竭的方法，但其存在供体匮乏的问题。人工肝可作为肝移植过渡支持手段。
目的：观察新型人源细胞混合型生物人工肝的安全性。
方法: 在全接触灌流型生物反应器接种微载体微重力中国人肝细胞系1细胞，结合血浆灌流对D-氨基半乳糖诱发急性肝功能衰竭模型食蟹猴进行治疗，治疗过程中观察循环管路的密闭性、不良反应及监测动物的生命体征变化，治疗结束后取灌流型生物反应器中的中国人肝细胞系1细胞，把细胞碎片与细胞分别接种至裸鼠的颈部、后背部皮下进行比较。
结果与结论：对急性肝功能衰竭食蟹猴模型的治疗过程中未发现循环管路中有液体渗漏，未发生出血、过敏、高热及其他严重的不良反应，生命体征平稳。接种后4周时，细胞碎片接种裸鼠未见接种部位出现种植瘤，细胞接种裸鼠共有10个接种部位出现肿瘤，致瘤率为100%。说明新型人源细胞混合型生物人工肝是安全可靠的，可进一步探讨其有效性，有望用于各种动物实验研究及各期临床实验研究。

关键词: 人肝细胞, 人工器官, 混合型, 肝, 安全性, 食蟹猴

Abstract:

BACKGROUND: At present, the only effective treatment is liver transplantation, but donor shortage is the main problem of liver transplantation, artificial liver can be served as a support means of liver transplantation in the transition.
OBJECTIVE: To observe the security of new human hepatocytes hybrid bioartificial liver.
METHODS: Chinese human liver cell line 1 (CL-1) cells, under micro carrier microgravity, which were injected into all the contact perfusion bioreactor inoculation, combined with plasma perfusion of D-galactosamine triggering acute liver failure of model treatment. The closure, adverse reactions and changes of monitoring animal vital signs were observed during the treatment. CL-1cells in were obtained in the perfusion bioreactor were obtained after treatment. The cellular debris and cells were inoculated into the neck and back of nude mice, respectively, and then underwent comparison.
RESULTS AND CONCLUSION: The liquid leakage was not found in the circulation channel, hemorrhage, allergies, high fever and other serious adverse reactions were also not found, vital signs were smooth and steady during the treatment of acute liver failure of model of cynomolgus. After four weeks of inoculation, planting tumor was not seen in nude mice with cellular debris inoculation, 10 vaccinal place occured tumor in nude mice with cellular debris inoculation, tumors rate was 100%. New human hepatocytes hybrid bioartificial liver is safe and validity and its effectiveness can be further explored. It is expected to be used for various animal experiment researches and each period clinical study.

中图分类号: